Fmoc-L-leucine, registered under CAS 35661-60-0, has the molecular formula C₂₁H₂₃NO₄ and a molecular weight of 353.41 g/mol. It is supplied as a white to off-white crystalline powder for Fmoc/tBu solid-phase peptide synthesis. The Fmoc group provides a base-labile α-amino protection that is cleaved with 20% piperidine in DMF, while the isobutyl side chain remains compatible with trifluoroacetic acid cleavage cocktails. Typical research-grade specifications include an HPLC area purity of not less than 98.0%, an enantiomeric purity of not less than 99.0%, and a specific rotation [α]_D²⁰ of -25.0° ± 2.0° at c=1 in DMF. Loss on drying by Karl Fischer titration is generally controlled at ≤ 0.50% for anhydrous material. Commercial models are differentiated chiefly by pack size, documentation tier, and residual solvent profile rather than by molecular structure: laboratory-scale bottles of 5 g, 25 g, and 100 g support discovery chemistry, whereas cGMP-grade lots are released against the same identity and purity platform with additional batch records for peptide active pharmaceutical ingredient campaigns.

Release testing is anchored to the Fmoc chromophore at 254 nm and to chiral stationary-phase HPLC

Reversed-phase HPLC with UV detection at 254 nm is the primary purity method because the fluorenylmethoxycarbonyl group absorbs strongly enough to allow area-% quantification down to 0.1% of oxidative and process impurities. Chiral purity is measured on a chiral stationary-phase column because the principal stereochemical risk is Fmoc-D-leucine, which becomes a diastereomeric defect in the final peptide. The specification for Fmoc-D-leucine is typically ≤ 0.5% in research-grade material and ≤ 0.3% in cGMP-grade material. Residual solvents are controlled under USP <467> and ICH Q3C; common residual species from the Fmoc protection and crystallization pathway include ethyl acetate, dichloromethane, and hexanes, with individual limits set at the concentration thresholds of the relevant ICH class. Loss on drying is determined by Karl Fischer coulometry or thermogravimetric analysis, and residue on ignition is used to exclude inorganic contamination. Each analytical method is bracketed by a system suitability injection that verifies resolution between Fmoc-L-leucine and the closest eluting Fmoc-protected amino acid or its enantiomer.

On automated peptide synthesizers configured for Fmoc chemistry, Fmoc-L-leucine is typically dissolved as a 0.1 M to 0.5 M stock in DMF or N-methyl-2-pyrrolidone (NMP). For a 0.1 mmol-scale resin loaded at 0.4–0.6 mmol/g, a fourfold excess of Fmoc-L-leucine relative to resin substitution is common, with activation by HBTU/HOBt/DIEA or by Oxyma and N,N′-diisopropylcarbodiimide (DIC). Deprotection between cycles uses 20% piperidine in DMF for 3 min followed by a second 10–15 min treatment; the dibenzofulvene-piperidine adduct is removed by DMF washes. Coupling completion is monitored by Kaiser, chloranil, or 2,4,6-trinitrobenzenesulfonic acid tests, and recoupling is applied when free amino groups persist. Because the leucine side chain is nonpolar and does not require side-chain protection, the building block avoids tertiary-butyl side-chain deprotection and simplifies global cleavage.

When a C-terminal leucine residue is required, preloaded resins are prepared by attaching Fmoc-L-leucine to 2-chlorotrityl chloride resin in dry dichloromethane with 3–4 equivalents of N,N-diisopropylethylamine and agitation for 2–4 h. Unreacted trityl chloride groups are capped with methanol, and resin loading is quantified by UV photometric measurement of the dibenzofulvene-piperidine adduct after deprotection. Typical measured substitutions range from 0.8 mmol/g to 1.5 mmol/g. This method places Fmoc-L-leucine at the C-terminus of the target peptide and is used when a bench-stable ester linkage is preferred over amide attachment. The procedure is sensitive to moisture, and dichloromethane containing > 0.05% water can depress resin loading by quenching the activated trityl cation.

How does residual Fmoc-D-leucine alter peptide diastereopurity?

Residual Fmoc-D-leucine introduces the D-leucine enantiomer at programmed L-leucine positions. In reversed-phase HPLC analysis of the final crude peptide, incorporation of a single D-leucine can shift retention time but may not fully resolve the diastereomer if hydrophobicity remains similar. Chiral amino acid analysis after hydrolysis, or enzymatic digestion with L-amino acid oxidase, is used to detect the substitution. The consequence is not merely an optical impurity; in peptide active pharmaceutical ingredients, a defined D-amino acid substitution can alter receptor binding, immunogenicity, and proteolytic stability. For this reason specification limits for Fmoc-D-leucine in Fmoc-L-leucine are tied to downstream diastereomer acceptance criteria rather than to raw-material purity alone. When a peptide contains leucine adjacent to bulky residues, a small percentage of D-enantiomer in the raw material can be amplified by slower coupling of the L-enantiomer if activation conditions are suboptimal, although published data for this specific configuration is limited. Monitoring of diastereomer formation at the peptide level is performed with high-resolution mass spectrometry and capillary electrophoresis or chiral HPLC after total hydrolysis.

A comparison of Fmoc-L-leucine with orthogonal protecting-group alternatives

Among Fmoc-protected amino acids, the selection of Fmoc-L-leucine rather than Fmoc-L-isoleucine or Fmoc-L-valine changes only the side-chain topology, but the kinetic consequences are measurable. The isobutyl group of leucine is not β-branched, allowing faster acylation than isoleucine or valine under standard carbodiimide/uronium activation. Fmoc-D-leucine is reserved for sequences where the D-configuration is intended, such as antimicrobial peptides and cyclic peptides that require stereochemical variation. Boc-L-leucine cannot be used in Fmoc/tBu SPPS because the Boc group is removed by trifluoroacetic acid while the Fmoc group is removed by piperidine; the opposite applies in Boc/Bzl SPPS. Cbz-L-leucine is removed by hydrogenolysis and is less convenient for automated cycles because catalytic hydrogenation is not readily implemented on resin. Fmoc-L-leucine also carries the Fmoc chromophore, enabling UV-based monitoring, whereas Boc- and Cbz-leucine lack this strong chromophore.

When Fmoc-L-leucine is used in solution-phase fragment condensation, the C-terminal carboxylic acid can be activated with DCC or DIC in dichloromethane or ethyl acetate at 0–5 °C, often with HOBt or HOAt to suppress racemization. The N-terminal Fmoc group remains intact during acid activation and permits selective deprotection after chain assembly. Solution-phase reactions are generally reserved for short peptides or building-block synthesis because the removal of DCC-derived dicyclohexylurea requires filtration, and residual urea can contaminate subsequent crystallizations. Fmoc-L-leucine is commonly converted to its N-hydroxysuccinimide ester or pentafluorophenyl ester for controlled acylation in organic media; these activated esters are stable enough to isolate but should be stored at −20 °C under desiccation. Published data for the specific coupling efficiency of isolated Fmoc-L-leucine pentafluorophenyl ester in aqueous DMF is limited, so each batch is confirmed by NMR and HRMS before use in a regulated sequence.

When microwave energy shortens coupling intervals but narrows the thermal window

Microwave-assisted solid-phase synthesis at 75 °C can reduce Fmoc-L-leucine coupling times from 30–60 min at room temperature to 5–10 min on commercial instruments operating at 20–50 W. The acceleration is significant for difficult sequences, but the permissible window is narrow because the Fmoc group is thermally vulnerable in the presence of residual secondary amine. Above 80 °C in DMF, premature Fmoc removal and dibenzofulvene scavenging compete with chain extension, leading to double couplings and premature termination. Pressure-rated reactor vials and fiber-optic temperature probes are used to maintain the set point within ± 5 °C of the target. When the sequence contains two consecutive leucine residues, microwave protocols may require double coupling at 50 °C rather than 75 °C to avoid deletion peptides, because resin-bound leucine residues can reduce solvation and hinder subsequent activation. NMP is sometimes substituted for DMF to lower vapor pressure during microwave heating; however, Fmoc-L-leucine solubility and activation efficiency are similar in both solvents.

Because the powder is hygroscopic after repeated opening, containers should be warmed to ambient temperature before weighing to avoid condensation on the solid. Anhydrous Fmoc-L-leucine dissolves readily in DMF and NMP at concentrations up to 0.5 M, but dissolution may be slower in dichloromethane. When a 0.1 M solution is prepared gravimetrically, the mass should be corrected for water content if the Karl Fischer value exceeds 0.50%. In automated synthesizer lines, particulate contamination from insoluble impurities is removed with 0.45 µm hydrophobic PTFE filters before the solution enters the coupling manifold. The compound should not be exposed to DMF containing free secondary amines or to peptide resins that have not been washed free of piperidine, because residual base initiates Fmoc cleavage before the desired coupling cycle. For difficult batch dissolution, brief sonication at 20–25 °C is preferred over heating above 30 °C to limit premature Fmoc loss.

Storage, incompatibilities, and pre-weighing moisture controls

Fmoc-L-leucine should be stored at −20 °C ± 5 °C in tightly sealed containers protected from light and moisture. Prolonged exposure to relative humidity above 60% can increase the Karl Fischer water content above 0.50% and reduce effective concentration when solutions are prepared gravimetrically. The compound is incompatible with strong bases, primary amines, and secondary amines because the Fmoc group is removed by β-elimination; even morpholine, hydroxylamine, or prolonged contact with DMF decomposition products can accelerate deprotection. It should not be dissolved in aqueous buffers at pH > 8 for solution-phase reactions unless immediate coupling is intended. For cGMP operations, a pre-weighing equilibration period of 30–60 min in a dry-room or nitrogen-purged glovebox is used to prevent moisture uptake. Amber glass or LDPE containers are acceptable if the container headspace is purged with nitrogen and resealed after each use.

Regulatory documentation for Fmoc-L-leucine intended for peptide active pharmaceutical ingredient manufacture includes residual solvent testing under USP <467> and ICH Q3C, elemental impurity data under ICH Q3D, and TSE/BSE statements because the product is synthetic and does not require animal-derived raw materials. The material is not a controlled substance and does not fall under REACH authorization categories, but a safety data sheet should be consulted before scale-up because the Fmoc group can release dibenzofulvene and piperidine adducts upon base contact. In process development, waste streams containing DMF and piperidine are segregated from aqueous acidic streams to avoid exothermic neutralization. Published data for the ecotoxicity of Fmoc-L-leucine specifically is limited; the generic assessment for Fmoc amino acids assumes low volatility and low aqueous solubility, with appropriate containment engineering to prevent dust generation during charging. Operators use local exhaust ventilation and nitrile gloves because the powder can cause mechanical eye irritation. No special air monitoring is required if containment is maintained below the relevant total dust occupational exposure limit.